KeyGene and LGC announced that they have extended their service license agreement to exploit KeyGene’s Sequence-Based Genotyping (SBG) technology for lab services.
LGC, Biosearch Technologies retains a worldwide non-exclusive license for the commercial offering and use of KeyGene’s patented SBG technology across all species and crops. The SBG patents protect highly cost-effective methods for identification and scoring of genetic markers, including SBG, Genotyping by Sequencing (GBS), double digest GBS (ddGBS) and related methods.
KeyGene licenses Sequence-Based Genotyping methods for commercial and research purposes. SBG is broadly recognised for its application for genetic analyses in plants, animals, micro-organisms and model species to, for example, characterise genomic diversity and improve traits.
Marcus Wills, global strategic development director, LGC, Biosearch Technologies, says, “We are delighted to be extending this successful partnership. KeyGene is a renowned market leader and technology innovator, and we see the continued presence of the SBG methodologies within our service offering as another significant step in serving the complete genotyping and marker discovery needs of our customers.”
Arjen van Tunen, CEO of KeyGene, says, “Through the renewal of the license agreement with LGC, our Sequence-Based Genotyping technology is once again licensed to a major player in life sciences. Being applied at LGC, our technology will continue to be used for their customers, who are working on healthy food, improved crops and sustainable environments.”
This license extension highlights LGC, Biosearch Technologies’ capabilities for supporting their customers’ breeding workflow and Next Generation Sequencing-based genotyping. They have recently signed partnership deals with Arbor Biosciences and Swift Biosciences to collaborate in genetic testing and marker discovery as well as targeted sequencing technology, as they continue to deliver custom sequencing solutions for the worldwide AgBio market.
